Ajanta Pharma shares edged higher after the company reported an 18% year-on-year rise in profit after tax to about Rs 267 crore for the fourth quarter of FY26, supported by strong traction in its US generics business and healthy overall revenue growth.
Consolidated revenue from operations climbed around 21% to roughly Rs 1,422 crore compared to the same period last year, signalling sustained demand across key markets despite cost pressures and forex headwinds.
The company’s US generics segment was a standout performer, with revenue reportedly surging by more than 50% year-on-year, aided by market share gains and the ramp-up of recent launches. Management commentary highlighted that the robust performance in the US, along with steady growth in branded generics across India and select emerging markets, helped offset the impact of higher expenses and mark-to-market forex losses.
On a full-year basis, Ajanta Pharma’s FY26 revenue rose about 17% to nearly Rs 5,453 crore, while net profit increased around 15% to roughly Rs 1,056 crore, underscoring consistent execution across its portfolio. With EBITDA also registering double-digit growth and margins staying healthy, investors viewed the latest quarterly print as a confirmation of the company’s ability to balance growth with profitability, which supported the positive movement in the stock post-results.
